This bill designates the facility of the United States Postal Service located at 340 East 1st Street in Tustin, California, as the "Ursula Ellen Kennedy Post Office Building".
This resolution designates July 2026 as "American Grown Flower and Foliage Month" to recognize and promote the domestic flower and foliage industry. The measure highlights the economic contributions of U.S. growers, noting that the sector supports thousands of jobs and small businesses while producing a wide variety of flowers across different states. It aims to encourage consumers to purchase locally grown floral products by raising awareness about the availability of domestic options and the benefits of supporting American agriculture. The Senate resolution formally acknowledges the role of these products in celebrating holidays and special occasions while urging the public to showcase American-grown flowers.
This resolution designates July 30, 2026, as "National Whistleblower Appreciation Day" to honor individuals who report misconduct, fraud, or abuse within the government. It requires federal agencies to inform employees, contractors, and the public about the legal protections available for reporting wrongdoing and to acknowledge the contributions whistleblowers make to saving taxpayer money. The bill does not create new laws or penalties but serves as a commemorative measure to encourage ethical reporting and recognize the role of whistleblowers in maintaining an ethical government.
HR 4541, the EARLY Act Reauthorization of 2025, extends the funding period for the Young Women’s Breast Health Education and Awareness program. It amends the Public Health Service Act to update the program’s expiration date from 2026 to 2031. The bill directly affects young women aged 15-25 by ensuring continued access to breast health education and awareness resources. The key provision is a simple extension of the existing program’s authorization period, without altering its scope or requirements. This is a procedural reauthorization to maintain current services through 2031.
This bill reauthorizes and expands the Accelerating Access to Critical Therapies for ALS Act through 2031, extending funding for research into treatments for amyotrophic lateral sclerosis. It requires drug manufacturers to share interim clinical trial data with the FDA to better assess the progress of investigational drugs and clarifies that phase 3 clinical trial definitions include combined phase 2/3 trials and planned trials not yet enrolling participants. The legislation also mandates the FDA to publish an updated five-year action plan for ALS and other rare neurodegenerative diseases, including resource needs and coordination strategies with broader disease communities. Additionally, the bill requires the Government Accountability Office to submit a report on the program's implementation four years after enactment.
The Main Street Capital Access Act reduces regulatory burdens for smaller banks, particularly those with less than $10 billion in assets. Key provisions include a 3-year phase-in period for new banks to meet capital requirements, lower leverage ratio requirements for rural banks (7.5% for the first 2 years), and a 30-day review process for business plan deviations. The bill also establishes an Office of Independent Examination Review, sets specific timelines for examinations (270 days) and reports (90 days), and creates a "least cost exception" for bank resolutions to prevent excessive concentration of the banking system. These changes aim to promote new bank formation, improve regulatory efficiency, and support community banking while maintaining financial stability.
This bill reauthorizes funding for the C.W. Bill Young Cell Transplantation Program, setting $31 million for fiscal year 2025 and $33 million annually for fiscal years 2027-2031. It also extends the deadline for the national cord blood inventory program from 2026 to 2031. The legislation directly affects stem cell research programs and cord blood banks by maintaining federal funding levels and prolonging the inventory program’s timeline. These provisions ensure continuity for existing research infrastructure and blood bank operations without introducing new policy changes.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
HR 2306 extends the Adams Memorial Commission's authority until 2032 and authorizes $50 million in federal funds for the memorial, requiring a 1:1 non-federal match and limiting administrative costs to 4% of federal funds. It updates location rules to allow the memorial within a designated area mapped by the Commission. The bill primarily affects the Adams Memorial Commission and entities contributing to the memorial's funding. It makes no new policy changes but adjusts procedural timelines and funding requirements for an existing commemorative project.
HR 2001 increases annual funding for a grant program supporting dental workforce development from $13.9 million to $15 million, extending the program through fiscal years 2026-2030 (previously 2019-2023) under the Public Health Service Act. The bill modifies existing funding levels to maintain support for addressing dental workforce shortages, with funds remaining available until expended. This change directly affects the operation of the grant program and its ability to fund dental workforce initiatives.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
